Analysis of Reported Adverse Events Linked to Platelet Aggregation Inhibitors on a Descriptive Basis

The use of platelet aggregation inhibitors leads to several adverse events and may reduce adherence to antiplatelet regimens and some of the events can be severe and even life-threatening. The present study aimed to describe the reported adverse events that were associated with platelet aggregation inhibitors. This was a retrospective study that included a descriptive analysis of the reported Adverse Events associated with platelet aggregation inhibitors using the FDA Adverse Event Reporting System (FAERS). The total number of adverse events reports was 110232 reports for aspirin use, 216 reports for cangrelor, 4406 reports for ci-lostazol, 21566 reports for clopidogrel, 3701 reports for dipyridamole, 968 reports for prasugrel, 1132 reports for ticlopidine, and 22311 reports for ticagrelor use. The present study showed that the use of platelet aggregation inhibitors causes several adverse events and that the most reported adverse event was hemorrhage, particularly gastrointestinal hemorrhage, and its consequences such as anemia, hypotension, and dyspnea. Healthcare providers should educate their patients about the adverse events that are associated with the use of platelet aggregation inhibitors and how to manage these events. They should also ensure that the drug is prescribed, dispensed, and used appropriately.